CN110237190A - A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine - Google Patents

A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine Download PDF

Info

Publication number
CN110237190A
CN110237190A CN201910680778.4A CN201910680778A CN110237190A CN 110237190 A CN110237190 A CN 110237190A CN 201910680778 A CN201910680778 A CN 201910680778A CN 110237190 A CN110237190 A CN 110237190A
Authority
CN
China
Prior art keywords
parts
western medicine
traditional chinese
chinese
stein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910680778.4A
Other languages
Chinese (zh)
Inventor
张媛媛
杨小龙
薛娟
刘运磊
李红梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yanan University Affiliated Hospital
Original Assignee
Yanan University Affiliated Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yanan University Affiliated Hospital filed Critical Yanan University Affiliated Hospital
Priority to CN201910680778.4A priority Critical patent/CN110237190A/en
Publication of CN110237190A publication Critical patent/CN110237190A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11Pteridophyta or Filicophyta (ferns)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535Perilla (beefsteak plant)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/63Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638Ligustrum, e.g. Chinese privet
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/68Plantaginaceae (Plantain Family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/756Phellodendron, e.g. corktree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/808Scrophularia (figwort)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/884Alismataceae (Water-plantain family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/898Orchidaceae (Orchid family)
    • A61K36/8984Dendrobium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a kind of improvement Stein-Leventhal syndrome therapy of combing traditional Chinese and Western medicine methods, the treatment method includes innerwear Chinese medicine preparation and injection Western medicine compound, the Chinese materia medica preparation is improved for patient's body basis, and the Western medicine compound is for promoting patient's body ovary ovulation function.The invention solves overcome prior art disadvantage, collaborative treatment of Chinese and western medicines, Chinese and western medical science combined treatment mode, Chinese materia medica preparation is mainly used for the conditioning of patient's body basis, and Western medicine compound is primarily to facilitate patient's body ovary ovulation function, complements each other, not only reduce drug side-effect, and quickly decorporation improves patient's constitution, reduces medicine band and carrys out side effect, has fabulous curative effect in the treatment of Stein-Leventhal syndrome.

Description

一种改善多囊卵巢综合征中西医结合治疗方法A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine

技术领域technical field

本发明涉及制药治疗方法技术领域,具体是指一种改善多囊卵巢综合征中西医结合治疗方法。The invention relates to the technical field of pharmaceutical treatment methods, in particular to a treatment method for improving polycystic ovary syndrome with integrated traditional Chinese and western medicine.

背景技术Background technique

多囊卵巢综合征至今病因不明,病机复杂,病情顽固,病程长,复发率高,临床治疗颇为棘手。The etiology of polycystic ovary syndrome is unknown so far, the pathogenesis is complicated, the condition is stubborn, the course of disease is long, the recurrence rate is high, and the clinical treatment is quite difficult.

PCOS患者目前常用避孕药达英-35,不能恢复女性生理-排卵月经周期;与非PCOS患者相比,PCOS患者静脉血栓栓塞性疾病的基线风险增加1.5倍,使用达英-35的患者增加3.7倍;其次,达英-35用于青春期PCOS的治疗中,很大程度上会抑制女孩身高生长。而螺内酯及二甲双胍均没有调节月经的作用。对于月经稀发或闭经的患者,长期服用螺内酯易发生子宫内膜增生或子宫内膜癌。有报道称二甲双胍在中孕期应用可能增加围生期胎儿死亡率,同时服用二甲双胍有些患者会出现胃肠道反应,如腹泻、恶心、呕吐、腹胀及厌食等。药物和手术促排卵有局限性,治疗时才能产生排卵并不能恢复自主排卵且不能长期使用,克罗米芬(CC)、尿促性腺激素(HMG)、人绒毛膜促性腺激素(HCG)会引起多胎、卵巢过度刺激综合征(OHSS)。卵巢楔形切除术、腹腔镜下卵巢打孔术虽避免了多胎妊娠,流产率低,但存在腹腔镜手术常规风险、粘连、损伤正常卵巢组织等不利因素。体外受精—胚胎移植(IVF-ET)治疗过程中则具有获卵数多、受精率低、OHSS发生率高的特点。Diane-35, a commonly used contraceptive pill for PCOS patients, cannot restore the female physiological-ovulatory menstrual cycle; compared with non-PCOS patients, the baseline risk of venous thromboembolic disease in PCOS patients increased by 1.5 times, and that of patients using Diane-35 increased by 3.7 Second, Diane-35 used in the treatment of adolescent PCOS can largely inhibit the growth of girls' height. Both spironolactone and metformin have no effect on regulating menstruation. For patients with oligomenorrhea or amenorrhea, long-term use of spironolactone is prone to endometrial hyperplasia or endometrial cancer. It has been reported that the application of metformin in the second trimester may increase perinatal fetal mortality, and some patients who take metformin at the same time may experience gastrointestinal reactions, such as diarrhea, nausea, vomiting, abdominal distension and anorexia. Drugs and surgical ovulation induction have limitations. Ovulation can only be produced during treatment and spontaneous ovulation cannot be restored, and it cannot be used for a long time. Clomiphene (CC), urinary gonadotropin (HMG), and human chorionic gonadotropin (HCG) can cause multiple births , Ovarian hyperstimulation syndrome (OHSS). Although ovarian wedge resection and laparoscopic ovarian drilling can avoid multiple pregnancy and have a low miscarriage rate, there are disadvantages such as conventional laparoscopic surgery risks, adhesions, and damage to normal ovarian tissue. In vitro fertilization-embryo transfer (IVF-ET) has the characteristics of large number of retrieved eggs, low fertilization rate and high incidence of OHSS.

中医认为多囊卵巢综合征病机为肾、肝和脾脏功能失调,痰浊、瘀血留滞,多属本虚标实之证。中医治疗多囊卵巢综合征的核心是辨证论治,常见证型为脾肾阳虚、痰瘀互结、肾虚血瘀、肾阴虚。治法集中在补肾、活血化瘀和祛湿化痰,少数根据辨证采用疏肝、健脾法;用药集中在补肾阳药、活血化瘀药和温化痰湿药。但单纯中医药治疗在临床上往往难以解决因持续不排卵所导致的闭经及月经失调、高雄激素所导致的多毛、痤疮等,所以在临床上常采用“中药联合口服避孕药物”的治疗模式;由于难以达到自主排卵的作用,对有生育要求者常采用“中药联合西药促排卵药物”的治疗模式。因此通过中西医结合的治疗方式是更为科学有效的治疗方法。Traditional Chinese medicine believes that the pathogenesis of polycystic ovary syndrome is kidney, liver and spleen dysfunction, phlegm turbidity, and stagnant blood stagnation, which mostly belong to the syndrome of deficiency in the root and excess in the superficiality. The core of TCM treatment of polycystic ovary syndrome is syndrome differentiation and treatment. The common syndrome types are spleen and kidney yang deficiency, phlegm and blood stasis, kidney deficiency and blood stasis, and kidney yin deficiency. The treatment methods focus on tonifying the kidney, promoting blood circulation to remove blood stasis, and dispelling dampness and resolving phlegm. A few of them use the method of soothing the liver and invigorating the spleen according to syndrome differentiation; However, it is often difficult to solve the amenorrhea and menstrual disorders caused by continuous anovulation, hirsutism and acne caused by hyperandrogen in clinical practice, so the treatment mode of "Chinese medicine combined with oral contraceptives" is often used clinically; Because it is difficult to achieve the effect of spontaneous ovulation, the treatment mode of "Chinese medicine combined with Western medicine to induce ovulation" is often used for those who have fertility requirements. Therefore, the combination of traditional Chinese and Western medicine is a more scientific and effective treatment method.

发明内容Contents of the invention

本发明要解决的技术问题是,克服现有技术缺点,提供一种改善多囊卵巢综合征中西医结合治疗方法,中西药结合治疗,中药制剂主要用于患者机体基础调理,西药组合物主要用于促进患者机体卵巢排卵功能。The technical problem to be solved by the present invention is to overcome the shortcomings of the prior art and provide a method for improving the treatment of polycystic ovary syndrome with integrated traditional Chinese and western medicine. The combination of traditional Chinese and western medicine is used for the basic conditioning of the patient's body, and the western medicine composition is mainly used for To promote the ovulation function of the patient's body.

为解决上述技术问题,本发明提供的技术方案为:一种改善多囊卵巢综合征中西医结合治疗方法,所述治疗方法包括内服中药制剂和注射西药组合物,所述中药制剂用于患者机体基础调理,所述西药组合物用于促进患者机体卵巢排卵功能。In order to solve the above technical problems, the technical solution provided by the present invention is: a method for improving the treatment of polycystic ovary syndrome with integrated traditional Chinese and Western medicine, the treatment method includes oral administration of traditional Chinese medicine preparations and injections of western medicine compositions, and the traditional Chinese medicine preparations are used for the patient's body. For basic conditioning, the western medicine composition is used to promote the ovarian ovulation function of a patient's body.

进一步的,所述中药制剂包括如下重量组份的原料:白苏子3-5份、黄柏4-6份、丹参3-7份、桃仁10-14份、玄参3-5份、石斛4-6份、布狗尾5-9份、刺柄莲座蕨4-6份、女贞子8-12份、泽泻4-6份、胡黄连5-9份、车前草10-14份、虎杖5-9份、珍珠草10-14份。Further, the traditional Chinese medicine preparation includes the following raw materials by weight: 3-5 parts of perilla seed, 4-6 parts of Cortex Phellodendri, 3-7 parts of Salvia miltiorrhiza, 10-14 parts of peach kernel, 3-5 parts of Scrophulariaceae, 4 parts of Dendrobium -6 parts, 5-9 parts of dogtail, 4-6 parts of rosette fern, 8-12 parts of Ligustrum lucidum, 4-6 parts of Alisma, 5-9 parts of berberine, 10-14 parts of plantain , 5-9 parts of knotweed, 10-14 parts of pearl grass.

进一步的,所述中药制剂的制备方法包括如下步骤:Further, the preparation method of the Chinese medicine preparation comprises the following steps:

1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;

2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;

3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.

进一步的,所述西药组合物包括含PCSK9抑制剂的生理盐水注射液。Further, the western medicine composition includes physiological saline injection containing PCSK9 inhibitor.

进一步的,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为1-8mg/Kg。Further, Alirocumab is selected as the PCSK9 inhibitor, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 1-8 mg/Kg.

进一步的,所述西药组合物注射10-30分钟内内服中药制剂。。Further, the traditional Chinese medicine preparation is taken orally within 10-30 minutes of injection of the western medicine composition. .

本发明具有如下优点:本发明解决了目前多囊卵巢综合征的常规治疗只能对症治疗以及现有治疗药物带来副作用的问题;而中西医学结合治疗方式,中药制剂主要用于患者机体基础调理,西药组合物主要用于促进患者机体卵巢排卵功能,相辅相成,不仅减少药物副作用,而且快速促排改善患者体质。本发明中通过各中药原料的合理配比,并利用各组分间的相互作用,其对多囊卵巢综合征患者的疗效好,其突出疗效表现在于能恢复患者的自主排卵月经周期,降低其高雄性激素及改善痤疮体征,具有安全性高且对人体的副作用小,减少危险性;本发明的西药组合物中经PCSK9抑制剂治疗,会使得低密度脂蛋白胆固醇下降,肝脏和卵巢中的脂滴含量下降,睾酮下降,卵巢形态有所改善,囊状卵泡减少,闭锁卵泡减少;卵巢排卵功能也有所改善,卵子质量提高。本发明的中西医结合治疗方式,在西药促排的基础上,快速改善患者内在体质,然后通过中药制剂维护内环境稳定,减少药物带来副作用,在多囊卵巢综合征的治疗具有极好的疗效。The present invention has the following advantages: the present invention solves the problem that the current conventional treatment of polycystic ovary syndrome can only be symptomatic treatment and the side effects caused by existing therapeutic drugs; while the combination of Chinese and Western medicine is the treatment method, and the traditional Chinese medicine preparation is mainly used for the basic conditioning of the patient's body The western medicine composition is mainly used to promote the ovarian ovulation function of the patient's body, complement each other, not only reduce the side effects of the medicine, but also quickly stimulate ovulation and improve the patient's physical fitness. In the present invention, through the rational proportioning of each Chinese medicine raw material and the interaction between each component, it has a good curative effect on patients with polycystic ovary syndrome, and its outstanding curative effect is that it can restore the patient's spontaneous ovulation menstrual cycle, reduce its High androgen and improvement of acne signs, high safety and small side effects on the human body, reducing risk; the western medicine composition of the present invention is treated with PCSK9 inhibitors, which will reduce low-density lipoprotein cholesterol, and lipids in the liver and ovary Droplet content decreased, testosterone decreased, ovarian shape improved, cystic follicles decreased, and atretic follicles decreased; ovarian ovulation function also improved, and egg quality improved. The integrated traditional Chinese and western medicine treatment method of the present invention, on the basis of promoting excretion of western medicine, quickly improves the patient's internal constitution, and then maintains the stability of the internal environment through traditional Chinese medicine preparations, reduces the side effects of the medicine, and has an excellent effect in the treatment of polycystic ovary syndrome. curative effect.

具体实施方式Detailed ways

下面结合实施例对本发明做进一步的详细说明。The present invention will be further described in detail below in conjunction with the examples.

一种改善多囊卵巢综合征中西医结合治疗方法,所述治疗方法包括内服中药制剂和注射西药组合物,所述中药制剂用于患者机体基础调理,所述西药组合物用于促进患者机体卵巢排卵功能。A treatment method for improving polycystic ovary syndrome with integrated traditional Chinese and Western medicine, said treatment method comprising oral administration of traditional Chinese medicine preparations and injections of western medicine compositions, said Chinese medicine preparations are used for the basic conditioning of the patient's body, and said western medicine compositions are used to promote the development of the patient's body's ovarian Ovulation function.

实施例1Example 1

所述中药制剂包括如下重量组份的原料:白苏子3份、黄柏4份、丹参3份、桃仁10份、玄参3份、石斛4份、布狗尾5份、刺柄莲座蕨4份、女贞子8份、泽泻4份、胡黄连5份、车前草10份、虎杖5份、珍珠草10份。The traditional Chinese medicine preparation includes the following raw materials by weight: 3 parts of perilla seed, 4 parts of Cortex Phellodendri, 3 parts of Salvia miltiorrhiza, 10 parts of peach kernel, 3 parts of Scrophulariaceae, 4 parts of dendrobium, 5 parts of dogtail cloth, 4 parts of rosette fern , 8 parts of Ligustrum lucidum, 4 parts of Alisma, 5 parts of Hu Huanglian, 10 parts of plantain, 5 parts of knotweed, and 10 parts of pearl grass.

所述中药制剂的制备方法包括如下步骤:The preparation method of described Chinese medicine preparation comprises the steps:

1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;

2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;

3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.

所述西药组合物包括含PCSK9抑制剂的生理盐水注射液,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为1mg/Kg。The western medicine composition includes a physiological saline injection containing a PCSK9 inhibitor, and the PCSK9 inhibitor is selected from Alirocumab, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 1 mg/Kg.

所述西药组合物注射10分钟内内服中药制剂。The traditional Chinese medicine preparation is taken orally within 10 minutes after injection of the western medicine composition.

实施例2Example 2

所述中药制剂包括如下重量组份的原料:白苏子5份、黄柏6份、丹参7份、桃仁14份、玄参5份、石斛6份、布狗尾9份、刺柄莲座蕨6份、女贞子12份、泽泻6份、胡黄连9份、车前草14份、虎杖9份、珍珠草14份。The traditional Chinese medicine preparation includes the following raw materials by weight: 5 parts of perilla seed, 6 parts of Cortex Phellodendri, 7 parts of Salvia miltiorrhiza, 14 parts of peach kernel, 5 parts of Scrophulariaceae, 6 parts of dendrobium, 9 parts of dogtail, 6 parts of rosette fern 12 parts of Ligustrum lucidum, 6 parts of Alisma, 9 parts of Hu Huanglian, 14 parts of plantain, 9 parts of knotweed, and 14 parts of pearl grass.

所述中药制剂的制备方法包括如下步骤:The preparation method of described Chinese medicine preparation comprises the steps:

1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;

2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;

3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.

所述西药组合物包括含PCSK9抑制剂的生理盐水注射液,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为8mg/Kg。The western medicine composition includes a physiological saline injection containing a PCSK9 inhibitor, and the PCSK9 inhibitor is selected from Alirocumab, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 8 mg/Kg.

所述西药组合物注射30分钟内内服中药制剂。The traditional Chinese medicine preparation is taken orally within 30 minutes after injection of the western medicine composition.

实施例3Example 3

所述中药制剂包括如下重量组份的原料:白苏子4份、黄柏5份、丹参5份、桃仁12份、玄参4份、石斛5份、布狗尾7份、刺柄莲座蕨5份、女贞子10份、泽泻5份、胡黄连7份、车前草12份、虎杖7份、珍珠草12份。The traditional Chinese medicine preparation includes the following raw materials by weight: 4 parts of perilla seed, 5 parts of Cortex Phellodendri, 5 parts of Salvia miltiorrhiza, 12 parts of peach kernel, 4 parts of Scrophulariaceae, 5 parts of dendrobium, 7 parts of dogtail cloth, 5 parts of rosette fern 10 parts of Ligustrum lucidum, 5 parts of Alisma, 7 parts of Hu Huanglian, 12 parts of plantain, 7 parts of Polygonum cuspidatum, and 12 parts of pearl grass.

所述中药制剂的制备方法包括如下步骤:The preparation method of described Chinese medicine preparation comprises the steps:

1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;

2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;

3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.

所述西药组合物包括含PCSK9抑制剂的生理盐水注射液,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为4mg/Kg。The western medicine composition includes a physiological saline injection containing a PCSK9 inhibitor, and the PCSK9 inhibitor is selected from Alirocumab, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 4 mg/Kg.

所述西药组合物注射20分钟内内服中药制剂。The traditional Chinese medicine preparation is taken orally within 20 minutes after injection of the western medicine composition.

白苏子:性味辛,温,无毒,功能主治下气,消痰,润肺,宽肠。治咳逆,痰喘,气滞便秘;Fructus Perillae: pungent in nature and flavor, warm, non-toxic, functions mainly for lowering qi, reducing phlegm, moistening the lungs, and widening the intestines. Cure cough, phlegm and asthma, qi stagnation and constipation;

黄柏:性味苦,寒,归肾、膀胱、大肠经;功能清热燥湿,泻火解毒,止血;Phellodendron Phellodendri: bitter in nature and flavor, cold, returns to kidney, bladder, large intestine meridian; function of clearing away heat and dampness, purging fire and detoxifying, hemostasis;

丹参:性味苦,微寒,归心、肝经;功能祛瘀止痛,活血通经,养心除烦,凉血消痈;Radix Salviae Miltiorrhizae: bitter in nature and flavor, be slightly cold, return heart, Liver Channel; Function dispelling blood stasis to relieve pain, promoting blood circulation to stimulate menstrual flow, nourishing the heart and relieving restlessness, cooling blood and eliminating carbuncle;

桃仁:性味苦、甘,平,归心、肝、大肠经;功能活血祛瘀、润肠通便;Peach kernel: bitter in nature and flavor, sweet, flat, heart-guiding, liver, and large intestine meridian; function of promoting blood circulation and removing blood stasis, moistening intestines and laxative;

玄参:性味甘,苦,咸,微寒,归肺、胃、肾经;功能清热凉血,滋阴泻火解毒;Radix Scrophulariae: sweet in nature and flavor, bitter, salty, slightly cold, returns to lung, stomach, kidney meridians; function of clearing heat and cooling blood, nourishing yin, purging fire and detoxifying;

石斛:性味甘,微寒,归胃、肾经;功能滋阴清热,益胃生津;Dendrobium: sweet in nature and flavor, slightly cold, returns to the stomach and kidney meridians; function nourishes yin and clears away heat, nourishes the stomach and promotes body fluid;

布狗尾:性味淡,凉。功能主治清热化痰,凉血止血,杀虫,用于感冒,咳嗽,疟疾,血丝虫病,小儿疳积,吐血,咯血,尿血;Cloth dog tail: light taste, cool. Functions and indications Clearing away heat and resolving phlegm, cooling blood to stop bleeding, killing parasites, used for colds, coughs, malaria, blood filariasis, malnutrition in children, vomiting blood, hemoptysis, hematuria;

刺柄莲座蕨:性味淡,涩,性凉,功能主治清热利湿;痰止咳;解毒消肿,主泄泻;痢疾;肺热咳嗽;瘰疬;痄腮;痈疖;骨折;毒蛇咬伤;Rosaceae spinosa: mild in taste, astringent, cool in nature, functions mainly for clearing heat and promoting dampness; phlegm and cough; detoxification and swelling, controlling diarrhea; dysentery; cough due to lung heat; scrofula; mumps; carbuncle furuncle; bone fracture; venomous snake bite hurt;

女贞子:性味甘,苦,凉,归肝、肾经;功能滋补肝肾,乌须明目;Ligustrum lucidum: sweet in nature and flavor, bitter, cool, returns to the liver and kidney meridians; function nourishes the liver and kidney, black hair improves eyesight;

泽泻:性味甘、寒,归肾、膀胱经;功能利水渗湿,泄热;Alisma: sweet and cold in nature and flavor, returns to the kidney and bladder meridian; functions in diuresis and dampness expelling, expels heat;

胡黄连:性味苦,寒,归肝、胃、大肠经;功能清湿热,退虚热,除疳热;Coptis chinensis: bitter in nature and flavor, cold, returns to liver, stomach, large intestine meridian; function of clearing away damp-heat, reducing asthenia-heat, removing malnutrition-heat;

车前草:性味甘寒,归肾、肝、肺经;功能利尿、清热、明目、祛痰;Plantain: sweet and cold in nature and flavor, returns to the kidney, liver, and lung meridians; functions diuresis, clearing away heat, improving eyesight, and eliminating phlegm;

虎杖:性味微苦,微寒,归肺、肝、胆经;功能清热解毒,利湿退黄,散瘀止痛,化痰止咳;Polygonum cuspidatum: slightly bitter in nature and flavor, slightly cold, returns to the lung, liver, and gallbladder meridian; function of clearing heat and detoxifying, promoting dampness and reducing jaundice, dissipating blood stasis and relieving pain, resolving phlegm and relieving cough;

珍珠草:性味苦,甘,凉,归肺、肝经;功能清热解毒,利湿退黄,明目,消积。Pearl grass: nature and flavor are bitter, sweet, cool, return lung, liver meridian; function heat-clearing and toxic substances removing, promoting dampness to reduce jaundice, improving eyesight, eliminating stagnation.

经实验对比,本发明中的治疗方式可以对多囊卵巢综合征的治疗具有极好的疗效。Through experimental comparison, the treatment mode in the present invention can have excellent curative effect on the treatment of polycystic ovary syndrome.

虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。Although the present invention has been described in detail with general descriptions and specific embodiments above, it is obvious to those skilled in the art that some modifications or improvements can be made on the basis of the present invention. Therefore, the modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the protection scope of the present invention.

Claims (6)

1. a kind of improvement Stein-Leventhal syndrome therapy of combing traditional Chinese and Western medicine method, which is characterized in that the treatment method includes interior Take traditional Chinese medicine preparation and injection Western medicine compound, and the Chinese materia medica preparation is used for the conditioning of patient's body basis, the Western medicine compound In promotion patient's body ovary ovulation function.
2. a kind of improvement Stein-Leventhal syndrome therapy of combing traditional Chinese and Western medicine method according to claim 1, which is characterized in that The Chinese materia medica preparation includes the raw material of following composition by weight: 3-5 parts of Perilla frutescens, 4-6 parts of Cortex Phellodendri, 3-7 parts of Radix Salviae Miltiorrhizae, peach kernel 10-14 Part, 3-5 parts of radix scrophulariae, 4-6 parts of dendrobium nobile, 5-9 parts of macrostachys uraria herb, 4-6 parts of handle lotus throne fern of thorn, 8-12 parts of the fruit of glossy privet, 4-6 parts of rhizoma alismatis, Hu 5-9 parts of the coptis, 10-14 parts of Asiatic plantain, 5-9 parts of polygonum cuspidate, 10-14 parts of Sagina subulata.
3. a kind of improvement Stein-Leventhal syndrome therapy of combing traditional Chinese and Western medicine method according to claim 1, which is characterized in that The preparation method of the Chinese materia medica preparation includes the following steps:
1) clean Chinese medicine material, is taken uniformly to mix according to enough numbers, twice using ethanol water refluxing extraction, for the first time With 8 times of 70% alcohol refluxs of amount 2 hours, filtering, second with 6 times of 70% alcohol refluxs of amount 1.5 hours, filter;Merge reflux Extracting solution, concentration, obtains alcohol extract;
2) it, by the dregs of a decoction of refluxing extraction in step 1, decocts and extracts twice, decoct 2 hours, mistake with 12 times of amount purified waters for the first time Filter decocts 1.5 hours, filtering with 8 times of amount purified waters for the second time;Combined extract, concentration, obtains aqueous extract;
3), above-mentioned alcohol extract and aqueous extract are merged, the ethanol water that percent by volume is calculated as 90% is added, it is heavy to stand It forms sediment, filtering, concentrated supernatant obtains clear cream, and the Chinese materia medica preparation taken after mixing it with water is made.
4. a kind of improvement Stein-Leventhal syndrome therapy of combing traditional Chinese and Western medicine method according to claim 1, which is characterized in that The Western medicine compound includes the normal saline solution of the inhibitor containing PCSK9.
5. a kind of improvement Stein-Leventhal syndrome therapy of combing traditional Chinese and Western medicine method according to claim 1, which is characterized in that The PCSK9 inhibitor selects Alirocumab, and the injection dosage of the normal saline solution is according to depending on by body weight 1-8mg/Kg。
6. a kind of improvement Stein-Leventhal syndrome therapy of combing traditional Chinese and Western medicine method according to claim 1, it is characterised in that: The Western medicine compound injects innerwear Chinese medicine preparation in 10-30 minutes.
CN201910680778.4A 2019-07-26 2019-07-26 A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine Pending CN110237190A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910680778.4A CN110237190A (en) 2019-07-26 2019-07-26 A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910680778.4A CN110237190A (en) 2019-07-26 2019-07-26 A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine

Publications (1)

Publication Number Publication Date
CN110237190A true CN110237190A (en) 2019-09-17

Family

ID=67893608

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910680778.4A Pending CN110237190A (en) 2019-07-26 2019-07-26 A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine

Country Status (1)

Country Link
CN (1) CN110237190A (en)

Similar Documents

Publication Publication Date Title
CN103432559B (en) Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof
CN104547961B (en) A kind of Chinese medicine composition for treating gall stone
CN103611021B (en) Be used for the treatment of medicine of Vesica sus domestica inflammation and preparation method thereof
CN105596861A (en) Pill used for treating adverse reaction after CT enhancement scanning and preparation method
CN102805834B (en) Drug for curing gastritis and preparation method thereof
CN101890081A (en) Formula of Chinese medicament for treating female infertility and processing method of Chinese medicament
CN104940718A (en) Pharmaceutical composition for treatment of chronic cholecystitis and preparation method thereof
CN110237190A (en) A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine
CN100374136C (en) A deer antler capsule
CN104771637A (en) Cholagogic and lithagogue agent for treating gallstone and preparation method thereof
CN103405554B (en) A drug used to cleanse the bowel before abdominal surgery
CN108186802A (en) A kind of Chinese medicine composition for preventing or treating leukoplakia vulvae and preparation method thereof
CN105727069A (en) Medicinal composition for treating chronic cholecystitis and preparation method for medicinal composition
CN103417772B (en) Oral bowel preparation medicine before gynecological operation
CN103417843B (en) A preparation method for Qingchang Granules before gynecological surgery
CN119548605A (en) A Chinese medicine composition for treating fractures and its application
CN105267895A (en) Medicine for treating bovine postpartum blood stasis type placenta retension and preparing method thereof
CN111467413A (en) A kind of traditional Chinese medicine composition for treating postpartum constipation and its preparation method and application
CN103405555B (en) A preparation method of Qingchang Granules for urological laparoscopic surgery
CN120037339A (en) A Chinese medicine formula for treating cough caused by mycoplasma pneumonia infection
CN117482175A (en) A kind of traditional Chinese medicine composition for treating diabetic nephropathy
CN104367862A (en) Traditional Chinese medicinal composition for treating urethral calculus
CN118045154A (en) A Chinese medicine composition for treating cholelithiasis and its preparation method and application
CN117731741A (en) A traditional Chinese medicine composition for treating liver fibrosis and early cirrhosis and its preparation method
CN104225506A (en) Medicinal preparation for treating thrombocytopenia after chemotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190917